JusticeItaly Official institution
Italy changes marketing authorization for cholesterol medicine Rovezet
Italy's medicines agency, AIFA, published an official notice in the Gazzetta Ufficiale on 31 October 2026 saying it has changed the marketing authorization for Rovezet, a human medicine. Rovezet combines rosuvastatin and ezetimibe, two ingredients used to lower cholesterol. The excerpt does not say what the change is, so the details must be checked in the full notice.
This summary was generated by AI; the official source prevails.
What does it mean?
Rovezet is a medicine that is allowed to be sold in Italy under an official permit, and that permit has now been changed. The notice does not say what the change is, so patients and pharmacists should check the full notice for details.
Who is affected?
Patients who use Rovezet and the pharmacies and companies that sell it in Italy.